HER2 status in esophagogastric cancer and patient outcomes
Part of Cancer, Digestive system clinical trials.
This study looks back at medical records of people with a certain type of esophageal or stomach cancer to see how HER2 status relates to patient outcomes. It may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of cancer called esophagogastric adenocarcinoma (cancer of the esophagus or stomach).
- Your tumor was tested for HER2 status (a protein that can affect cancer growth).
- You are 18 years old or older.
- You were diagnosed between the year 2000 and April 2024.
- Your cancer is not a type called squamous cell carcinoma of the esophagus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps an organized record of people diagnosed with esophagus, gastroesophageal junction, or stomach cancer. It helps researchers learn from real-world outcomes, based on health information collected over time.
This study looks back at past patients’ medical and pathology records from esophageal cancer surgeries. It may help improve how doctors understand which advanced tumors should be treated, by reviewing outcomes in specific tumor stages.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial tests two targeted medicines, trastuzumab and pertuzumab (HER2-blocking drugs), given before surgery for HER2-positive esophageal or stomach-esophagus junction cancer. The goal is to shrink the tumor and improve how well surgery works and outcomes after treatment.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.